An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Massachusetts Attorney General ...
I open my emails to find yet another message from a patient about their amphetamine-dextroamphetamine (the generic form of Aderall) no longer working. Dr. Plutchik, my meds no longer seem to be ...
18d
Ensuring Purity and Performance: The Rise of Top Pharmaceutical and Electrochemical Manufacturers
HANGZHOU CITY, ZHEJIANG, CHINA, January 19, 2026 /EINPresswire.com/ -- With the development of the pharmaceutical and ...
U.S. District Judge Cynthia Rufe of the Eastern District of Pennsylvania granted final approval of a $200 million settlement between end-payer plaintiffs and Sun Pharmaceutical Industries and Taro ...
SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that lead to major medical advances -- but it ...
Generic drugs are the rare part of American health care that actually drives down costs. In 2024, they accounted for 90 percent of all prescriptions filled in the United States yet accounted for only ...
The companies, which are yet to announce the approval, did not immediately respond to Reuters' request for a comment. Sun Pharma, which is India's largest drugmaker by revenue, on Friday announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results